> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/cancer-immunology/what-is-cancer-immunotherapy.md).

# What Is Cancer Immunotherapy?

{% hint style="info" %}
This page explains cancer immunotherapy for patients, supporters, and practitioners.

It covers how these treatments work, where evidence is strongest, and where uncertainty remains.
{% endhint %}

### Part one: guide topics

* [The core idea](#part-one-the-core-idea-your-immune-system-already-knows-how-to-fight-cancer)
* [Where it works well and where it struggles](#where-immunotherapy-works-well-and-where-it-struggles)
* [The cancer-immunity cycle](#the-cancer-immunity-cycle)
* [Hot and cold tumours](#hot-and-cold-tumours)
* [Safety and immune-related side effects](#safety-and-immune-related-side-effects)
* [Why responses differ](#why-responses-differ)
* [Understanding evidence levels](#understanding-evidence-levels)
* [Questions for a clinic or treatment team](#questions-for-a-clinic-or-treatment-team)

### Part two: treatment types

* [Treatment types overview](#immunotherapy-is-not-one-treatment)
* [1. Checkpoint inhibitors](#1-checkpoint-inhibitors)
* [2. Personalised mRNA neoantigen vaccines](#2-personalised-mrna-neoantigen-vaccines)
* [3. Other cancer vaccines](#3-other-cancer-vaccines)
  * [3.1 Off-the-shelf peptide vaccines](#31-off-the-shelf-peptide-vaccines)
* [4. Dendritic-cell therapy](#4-dendritic-cell-therapy)
* [5. CAR-T cell therapy](#5-car-t-cell-therapy)
* [6. TIL therapy](#6-til-therapy)
* [7. NK cell therapy](#7-nk-cell-therapy)
* [8. Bispecific antibodies](#8-bispecific-antibodies)

### Part one: The core idea: your immune system already knows how to fight cancer

The immune system does more than fight infection. It continually surveys the body for damaged or abnormal cells.

Cancer can grow when this surveillance fails. Tumours may hide from immune cells. They may also send signals that suppress an immune response.

**Immunotherapy** is an umbrella term for treatments that help the immune system recognise or respond to cancer. Some release inhibitory signals. Others add, redirect, or expand immune cells.

This differs from surgery, which removes tumour tissue. It also differs from chemotherapy, which mainly targets rapidly dividing cells.

Immunotherapy works with immune biology. That creates opportunities and distinctive risks.

### Where immunotherapy works well and where it struggles

Immunotherapy does not work equally across cancers. Response depends on tumour biology, immune context, biomarkers, and treatment setting.

Checkpoint inhibitors have established roles in cancers such as melanoma, kidney cancer, bladder cancer, selected lung cancers, and some head and neck cancers. They can also work especially well in tumours with **dMMR** or **MSI-H** features.

CAR-T therapy has established roles in selected blood cancers. These include some leukaemias, lymphomas, and multiple myeloma settings.

Other cancers remain difficult. Most pancreatic cancers, glioblastomas, many prostate cancers, most microsatellite-stable colorectal cancers, and many ovarian cancers resist checkpoint therapy alone.

A tumour may resist because few T cells reach it. It may lack visible targets. It may also create a strongly suppressive microenvironment.

### The cancer-immunity cycle (CIC)

The cancer-immunity cycle describes the steps needed for an immune response to destroy tumour cells. A problem at any step can limit treatment response.

**More reports on each of these CIC steps is coming soon to the hub.**

1. **Antigen release:** Tumour cells must release recognisable fragments after damage or death. Treatments like chemotherapy, radiation, and some targeted therapies can trigger this release, which is why they are sometimes combined with immunotherapy.
2. **Antigen presentation:** Dendritic cells collect these fragments, process them, and carry them to nearby lymph nodes to present to T cells. If too few dendritic cells are active — or if the tumour suppresses them — this handover does not happen reliably.
3. **T-cell priming:** T cells become activated against the tumour target and commit to hunting it. This is the step where CTLA-4 checkpoint inhibitors (such as ipilimumab) do most of their work — they help T cells get fully switched on rather than standing down too early.
4. **T-cell trafficking:** Activated T cells travel through the bloodstream toward the tumour. Some tumours secrete signals that actively repel immune cells before they can arrive, making this a surprisingly common point of failure.
5. **T-cell infiltration:** T cells must leave the bloodstream and physically enter the tumour tissue. Tumours with few immune cells inside them are often called "cold" — releasing immune brakes does not help much if there is no immune army present to release.
6. **Recognition:** T cells must identify cancer cells as abnormal, typically by reading identity tags (MHC) displayed on the cell surface. Tumours that remove or hide these tags can evade detection at this step.
7. **Killing:** T cells must destroy their target cells and sustain that effort against active suppression. The tumour microenvironment can deploy signals — including PD-L1, TGF-β, and adenosine — that exhaust or silence T cells before the job is done. PD-1/PD-L1 checkpoint inhibitors act mainly here.

Checkpoint inhibitors often help most at the recognition and killing stages (Steps 6,7). They cannot solve every earlier barrier.

For example, releasing an immune brake may not help if T cells cannot enter the tumour. Combination research aims to address several blocked steps together.

[Gamma–delta T cells in cancer: a 2026 research review](/myhealingcommunity-docs/cancer-immunology/gamma-delta-t-cells-in-cancer-a-2026-research-review.md) examines cells that may detect stressed tumour cells without classical MHC recognition (Step 6).

***

### Hot and cold tumours

“Hot” and “cold” are shorthand terms for a tumour’s immune environment.

A **hot tumour** already contains immune cells and inflammatory signals. It may also have features that make it easier to recognise. Checkpoint inhibitors can work well in this setting.

A **cold tumour** contains few active T cells. It may lack visible antigens or exclude immune cells physically. Releasing immune brakes alone often has little effect.

Researchers are studying ways to make cold tumours more responsive. Approaches include vaccines, cell therapies, radiation, oncolytic viruses, and microenvironment-targeted combinations.<br>

***

### Safety and immune-related side effects

Immunotherapy can be better tolerated than chemotherapy in some ways. It can also cause unique toxicities.

Checkpoint inhibitors can trigger **immune-related adverse events**, or irAEs. The activated immune system may attack healthy tissue.

These events can affect the skin, bowel, lungs, liver, hormone glands, nervous system, or heart. They can develop during treatment or after it ends.

CAR-T therapy can cause cytokine release syndrome and neurological toxicity. These reactions require prompt specialist assessment and management.

{% hint style="danger" %}
New diarrhoea, breathlessness, chest pain, fever, confusion, severe weakness, or jaundice need urgent clinical review during or after immunotherapy.
{% endhint %}

***

### Why responses differ

Several features can influence whether checkpoint therapy is likely to help.

* **Tumour mutational burden** can increase the number of visible abnormal targets.
* **PD-L1 expression** may indicate checkpoint signalling, but it is an imperfect marker.
* **MSI-H or dMMR status** can make tumours more responsive to checkpoint treatment.
* **T-cell infiltration** and the wider tumour microenvironment influence whether immune cells can act.
* Prior treatments, general health, and the gut microbiome may also affect immune fitness.

No single biomarker gives a complete answer. Results should be interpreted alongside cancer type, stage, prior treatment, and the proposed regimen.

***

### Understanding evidence levels

{% hint style="info" %}
The evidence label matters as much as the scientific rationale.

* **Preclinical** evidence comes from cell or animal models. It does not establish human benefit.
* **Phase I trials** mainly assess safety and dose.
* **Phase II trials** look for early signs of activity.
* **Phase III trials** compare a treatment with current care in larger groups.
* **Regulatory approval** applies to a specific treatment, cancer setting, and indication.

An unapproved treatment may have a plausible rationale. It may still lack reliable evidence of patient benefit.
{% endhint %}

***

### Questions for a clinic or treatment team

Use these questions when discussing immunotherapy, especially outside standard care pathways.

1. What exact treatment do you recommend, and what is its regulatory status?
2. What published evidence supports this treatment for my cancer and stage?
3. What response rate and risks apply to my treatment setting?
4. Who will manage side effects after treatment ends or after I return home?
5. Will you share full treatment records with my local oncology team?

***

## Part two

### Treatment types

This part compares the main cancer immunotherapy treatment types. They work through different immune mechanisms and suit different cancer settings.

Some treatments are established care for specific cancers. Others remain available only through clinical trials. Evidence, access, benefits, and risks can differ greatly between approaches.

Use these sections to understand what each treatment does. Discuss suitability with a specialist team that knows your cancer and treatment history.

#### Jump to a treatment

* [1. Checkpoint inhibitors](#1-checkpoint-inhibitors)
* [2. Personalised mRNA neoantigen vaccines](#2-personalised-mrna-neoantigen-vaccines)
* [3. Other cancer vaccines](#3-other-cancer-vaccines)
  * [3.1 Off-the-shelf peptide vaccines](#31-off-the-shelf-peptide-vaccines)
* [4. Dendritic-cell therapy](#4-dendritic-cell-therapy)
* [5. CAR-T cell therapy](#5-car-t-cell-therapy)
* [6. TIL therapy](#6-til-therapy)
* [7. NK cell therapy](#7-nk-cell-therapy)
* [8. Bispecific antibodies](#8-bispecific-antibodies)

### 1. Checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) are the most common modern form of cancer immunotherapy. They block molecular brakes that can stop T cells from attacking.

The main targets include **PD-1**, **PD-L1**, **CTLA-4**, and **LAG-3**. Examples include pembrolizumab, nivolumab, and ipilimumab.

These treatments can produce durable benefit in selected cancers. They work best when a tumour already has a recognisable immune response.

***

### 2. Personalised mRNA neoantigen vaccines

Personalised mRNA neoantigen vaccines sequence a patient’s tumour. They identify tumour-specific mutations, then create a vaccine against those targets. Each vaccine is different because each tumour is different.

Five-year KEYNOTE-942 data showed promising results in high-risk melanoma. Intismeran plus pembrolizumab reduced recurrence or death by 49% versus pembrolizumab alone. At five years, 68.8% of vaccine-group patients remained cancer-free. Distant-metastasis risk fell by 59%.

In pancreatic cancer, early results showed durable T-cell responses four years after the final dose. Six of eight responders remained cancer-free over three years after surgery. A global Phase III trial is underway.

These are early-phase findings. Long-lived T-cell memory is encouraging. Larger trials must still confirm patient benefit.

{% hint style="info" %}
Personalised mRNA cancer vaccine regulatory status as of mid-2026

Personalised mRNA cancer vaccines are not yet approved for use outside clinical trials in any country. Intismeran autogene (mRNA-4157/V940) holds FDA Breakthrough Therapy Designation in the US and EMA PRIME Designation in Europe — both fast-track statuses that accelerate review but are not approvals. **The Phase III trial (INTerpath-004)** is currently recruiting in Australia, the US, Europe, Canada, Brazil, Argentina, and several other countries.<br>

What this means in practice: The only way to access this vaccine right now is through a clinical trial. No private clinic — in Germany, Mexico, or anywhere else — can legally offer intismeran autogene outside of that trial setting. If a clinic claims to offer a personalised mRNA neoantigen vaccine, ask specifically which product, which trial, and where the regulatory authorisation sits.
{% endhint %}

***

### 3. Other cancer vaccines

Outside the personalised neoantigen approach (above), three therapeutic cancer vaccines hold full regulatory approval and are available in standard clinical settings.

**Sipuleucel-T (Provenge)** is FDA-approved for advanced prostate cancer. It was the first therapeutic cancer vaccine approved anywhere. Clinicians collect a patient’s immune cells, stimulate them with a prostate-cancer protein, and return them to prime an immune response. It extended median survival by about four months in trials.

**T-VEC (Imlygic)** is approved for unresectable advanced melanoma. It is a modified cold-sore virus injected into accessible tumours. It kills cancer cells and releases immune signals. It is the only oncolytic virus therapy with FDA and EMA approval.

**BCG** has treated early-stage bladder cancer for decades. It is placed directly in the bladder after surgery. It triggers local immune activity and reduces recurrence. It remains standard care in this setting.

***

#### 3.1 Off-the-shelf peptide vaccines

These vaccines are pre-manufactured preparations. They target proteins shared across many tumours. They do not target mutations unique to one patient.

Many private clinics offer them as “cancer vaccines.” They can generate measurable T-cell responses. However, large trials have not clearly demonstrated benefit when they are used alone.

They may have a supporting role while a personalised vaccine is manufactured. That process can take several weeks.

***

### 4. Dendritic-cell therapy

Dendritic-cell (DC) therapy takes a step further back in the process. Dendritic cells are the immune system's messenger cells: they collect fragments of foreign or abnormal material, process them, and carry them to T cells to trigger a targeted response. In DC therapy, a patient's own dendritic cells are collected, loaded with tumour material in a laboratory, and returned to the body to stimulate an attack.

Clinical data show that measurable T-cell activation occurs in a majority of patients — roughly 77% in some prostate cancer studies and 61% in kidney cancer studies. Translating that immune activation into clear tumour shrinkage has proven harder: objective response rates in systematic reviews sit in the 7–16% range depending on cancer type.

Where DC therapy appears to add the most value is in extended survival rather than rapid tumour reduction, and results are expected to improve as DC protocols are combined with checkpoint inhibitors. The science is genuinely promising; the trial data needed to confirm it in most cancer types is still being gathered.

***

### 5. CAR-T cell therapy

CAR-T therapy collects T cells and engineers them in a laboratory. The cells receive a new receptor that recognises a chosen cancer target.

The expanded cells are then infused back into the patient. CAR-T has transformed treatment for selected blood cancers.

Solid tumours remain harder. Engineered cells must reach the tumour, survive there, and keep functioning within a suppressive environment.<br>

***

### 6. TIL therapy

TIL therapy expands immune cells already found within a patient’s tumour. Unlike CAR-T, it does not engineer a new receptor onto those cells.

The expanded cells are then returned to the patient. Lifileucel (Amtagvi) received FDA accelerated approval in 2024 for advanced melanoma after checkpoint-inhibitor treatment.

TIL therapy is also in trials for lung, cervical, and head and neck cancers. It uses the patient’s own tumour-infiltrating cells.

***

### 7. NK cell therapy

NK cells are rapid-response immune cells. They can kill stressed or abnormal cells without conventional antigen recognition.

This may matter when tumours reduce MHC expression. Conventional T cells depend on MHC for recognition. [Gamma–delta T cells](/myhealingcommunity-docs/cancer-immunology/gamma-delta-t-cells-in-cancer-a-2026-research-review.md) may address the same problem differently.

**Anktiva** is an IL-15 receptor agonist developed by ImmunityBio. It activates NK cells and CD8 T cells. It received FDA approval in 2024 for BCG-unresponsive non-muscle-invasive bladder cancer.

Interim bladder-cancer analyses reported complete remission in 85% of participants. Durable responses extended beyond 47 months in some patients. These findings apply to this specific treatment and indication.

NK-cell infusions are also offered by private clinics. These products are separate from approved Anktiva treatment and ImmunityBio trials.

A 2024 systematic review found promising early signals in solid tumours. Standalone NK-cell infusions remain earlier-stage treatments. They should not be conflated with approved Anktiva treatment.

***

### 8. Bispecific antibodies

Bispecific antibodies are engineered proteins with two arms. One arm locks onto a cancer cell. The other grabs a nearby T cell.

They physically bridge both cells. This forces direct contact so the T cell can kill.

This may overcome a key immune-evasion strategy. Tumours can hide from T cells before they get close enough to act.

Fifteen bispecific antibodies now hold FDA approval. Most treat blood cancers. Several also hold EMA or TGA approval.

#### Blood cancers

**Blinatumomab (Blincyto)** was the first approved bispecific antibody in 2014. It treats B-cell acute lymphoblastic leukaemia. It is approved in the US, EU, and Australia.

**Teclistamab (Tecvayli)** and **elranatamab (Elrexfio)** treat relapsed or refractory multiple myeloma. Both hold US and EU approval. Tecvayli also holds TGA approval.

**Talquetamab (Talvey)** treats multiple myeloma. It received provisional TGA approval in July 2025.

**Epcoritamab (Epkinly)** and **glofitamab (Columvi)** treat diffuse large B-cell lymphoma and related lymphomas. Both hold TGA approval. Glofitamab is not yet publicly funded through the PBS.

**Mosunetuzumab (Lunsumio)** treats follicular lymphoma. It holds FDA and EMA approval.

#### Solid tumours

**Tarlatamab (Imdelltra)** treats small-cell lung cancer. The FDA approved it in May 2024. It was among the first bispecifics approved for a solid tumour.

**Amivantamab (Rybrevant)** treats EGFR/MET-mutated non-small-cell lung cancer. It holds FDA and EMA approval.

**Tebentafusp (Kimmtrak)** treats uveal melanoma, a rare eye cancer. It holds FDA and EMA approval.

Bispecific antibodies are hospital-administered drugs. They require careful monitoring for cytokine release syndrome and infection risk.

Unlike NK-cell therapy or dendritic-cell preparations, they are not usually offered by private clinics in Mexico or Germany outside standard care. Unstructured overseas access would be unusual.

Some German private clinics use them within structured off-label protocols. This requires established relationships with the approving institutions.

Researchers are studying many more bispecific antibodies. Trials include solid tumours and checkpoint-inhibitor combinations.

***

{% hint style="warning" %}
Being offered by a clinic does not establish effectiveness. Ask whether the exact treatment is approved, trial-based, or experimental.
{% endhint %}

***

### Clear takeaways

* Immunotherapy is a broad treatment category, not one drug or approach.
* It can create lasting benefit in selected cancers and biomarker-defined settings.
* Many tumours still resist immunotherapy because multiple immune-cycle steps are blocked.
* The strength of evidence differs greatly between approved care and investigational offerings.
* Side-effect monitoring and communication between treatment teams are essential.

### Further reading

* [National Cancer Institute: Immunotherapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy)
* [National Cancer Institute: T-cell transfer therapy](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy)
* [Cancer Research Institute: The cancer-immunity cycle](https://www.cancerresearch.org/what-is-immunotherapy/impact-of-immunotherapy/cancer-immunity-cycle)
* [National Cancer Institute: Biomarker testing for cancer treatment](https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment)

### References

1. Zhang M, et al. “[Advances in cancer immunotherapy: historical perspectives, current challenges, and future directions](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057291/).” *Frontiers in Immunology*. 2025.
2. Zugasti I, et al. “[CAR-T cell therapy for cancer: current challenges and future directions](https://doi.org/10.1038/s41392-025-02269-w).” *Signal Transduction and Targeted Therapy*. 2025.
3. Mellman I, et al. “[The cancer-immunity cycle: indication, genotype, and environment](https://pubmed.ncbi.nlm.nih.gov/37820582/).” *Nature Medicine*. 2023.
4. Zhu Y, et al. “[Current state of cancer immunity cycle: new strategies and challenges](https://pmc.ncbi.nlm.nih.gov/articles/PMC11926806/).” *Frontiers in Immunology*. 2025.
5. Tufail M, et al. “[Immune evasion in cancer: mechanisms and cutting-edge therapies](https://doi.org/10.1038/s41392-025-02280-1).” *Signal Transduction and Targeted Therapy*. 2025.
6. Sethna Z, et al. “[RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic ductal adenocarcinoma](https://doi.org/10.1038/s41586-024-08508-4).” *Nature*. 2025.
7. Weber JS, et al. KEYNOTE-942 five-year analysis. “[Individualised neoantigen therapy mRNA-4157 plus pembrolizumab in resected high-risk melanoma](https://pubmed.ncbi.nlm.nih.gov/41632561/).” *Journal of Clinical Oncology*. 2026.
8. Magoola M, et al. “[Current progress and future perspectives of RNA-based cancer vaccines](https://pmc.ncbi.nlm.nih.gov/articles/PMC12153701/).” *Frontiers in Immunology*. 2025.
9. Ruzzi F, et al. “[Cancer vaccines: target antigens, vaccine platforms and recent advances](https://doi.org/10.1016/j.mam.2024.101323).” *Molecular Aspects of Medicine*. 2025.
10. Chen Q, et al. “[Cancer and treatment-specific incidence rates of immune-related adverse events: a systematic review](https://doi.org/10.1038/s41416-024-02887-1).” *British Journal of Cancer*. 2024.
11. Yin Q, et al. “[Immune-related adverse events of immune checkpoint inhibitors: a review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10247998/).” *Frontiers in Immunology*. 2023.
12. Moini K, et al. “[Recurrent pancreatic cancer treated with N-803 (Anktiva) and PD-L1 targeted immunotherapy](https://pmc.ncbi.nlm.nih.gov/articles/PMC11954496/).” *Frontiers in Oncology*. 2024.

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Discuss treatment choices with a qualified oncology team.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.

## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/cancer-immunology/what-is-cancer-immunotherapy.md?ask=<question>&goal=<endgoal>
```

`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.

The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.